Sanofi India net moves up by 37.5% in Q1, Charles Billard will be new CFO

New Delhi: Drug firm Sanofi India on Tuesday reported 37.27 per cent rise in net profit to Rs 82.5 crore for the quarter ended March 31, 2018.

The company had posted a net profit of Rs 60.1 crore in January-March period of 2016-17, Sanofi India said in a filing to BSE.

Total revenue from operations also rose to Rs 617.7 crore as against Rs 552.9 crore earlier, it added.

In a separate filing , the company said its board has approved appointment of Charles Billard as Chief Financial Officer and key Managerial Personnel with effect from July 1, 2018.

Shares of Sanofi India were today trading at Rs 4,890.85 per scrip on BSE, up 1.17 per cent from its previous close.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert